Atea’s most advanced antiviral drug candidate, AT-527, is being evaluated in a multi-national multi-center Phase 2 clinical trial for the treatment of patients with moderate COVID-19 and risk factors for poor outcomes. As an orally-administered direct-acting antiviral, AT-527 is designed to arrest the progression of COVID-19 by inhibiting replication of the SARS CoV-2 virus.
Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.
Leveraging our platform, we have discovered and are rapidly advancing novel oral direct-acting antiviral drug candidates. Utilizing unique chemical modifications, these product candidates are designed to have the potential for enhanced antiviral activity and selectivity.
See updates on AT-527, other Atea product candidates and company news.
BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections,
Experienced Financial Executive Brings Leadership and Public Company Expertise BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to
Full Exercise of the Underwriters’ Overallotment Brings Additional $45 Million BOSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to
Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.
Copyright © 2020 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use